New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors Detailed...
Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...
Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...
Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation...
New Drug Application (NDA) supported by positive Phase 3 RINGSIDE results, including significant improvement in progression-free survival vs. placebo (hazard ratio = 0.16, p
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation...
New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 IM-1021 Phase 1 ongoing with initial data expected in 2026 Three...